167 related articles for article (PubMed ID: 36398446)
21. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.
Pavlovic J; Greenland P; Deckers JW; Brugts JJ; Kavousi M; Dhana K; Ikram MA; Hofman A; Stricker BH; Franco OH; Leening MJ
JAMA Cardiol; 2016 Sep; 1(6):708-13. PubMed ID: 27439175
[TBL] [Abstract][Full Text] [Related]
22. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease.
Gillette-Guyonnet S; Andrieu S; Dantoine T; Dartigues JF; Touchon J; Vellas B;
Alzheimers Dement; 2009 Mar; 5(2):114-21. PubMed ID: 19328438
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Multidomain Interventions on Global Cognition, Symptoms of Depression and Apathy - A Pooled Analysis of Two Randomized Controlled Trials.
den Brok MGHE; Hoevenaar-Blom MP; Coley N; Andrieu S; van Dalen J; Meiller Y; Guillemont J; Brayne C; van Gool WA; Moll van Charante EP; Richard E
J Prev Alzheimers Dis; 2022; 9(1):96-103. PubMed ID: 35098979
[TBL] [Abstract][Full Text] [Related]
24. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study.
Pavlović J; Greenland P; Deckers JW; Kavousi M; Hofman A; Ikram MA; Franco OH; Leening MJ
Eur J Prev Cardiol; 2018 Mar; 25(4):420-431. PubMed ID: 29171772
[TBL] [Abstract][Full Text] [Related]
25. Body, Brain, Life for Cognitive Decline (BBL-CD): protocol for a multidomain dementia risk reduction randomized controlled trial for subjective cognitive decline and mild cognitive impairment.
McMaster M; Kim S; Clare L; Torres SJ; D'Este C; Anstey KJ
Clin Interv Aging; 2018; 13():2397-2406. PubMed ID: 30538436
[TBL] [Abstract][Full Text] [Related]
26. Multidomain Interventions to Prevent Cognitive Impairment, Alzheimer's Disease, and Dementia: From FINGER to World-Wide FINGERS.
Rosenberg A; Mangialasche F; Ngandu T; Solomon A; Kivipelto M
J Prev Alzheimers Dis; 2020; 7(1):29-36. PubMed ID: 32010923
[TBL] [Abstract][Full Text] [Related]
27. Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review.
Coley N; Giulioli C; Aisen PS; Vellas B; Andrieu S
Ageing Res Rev; 2022 Dec; 82():101777. PubMed ID: 36336171
[TBL] [Abstract][Full Text] [Related]
28. Dementia risk scores as surrogate outcomes for lifestyle-based multidomain prevention trials-rationale, preliminary evidence and challenges.
Coley N; Hoevenaar-Blom MP; van Dalen JW; Moll van Charante EP; Kivipelto M; Soininen H; Andrieu S; Richard E;
Alzheimers Dement; 2020 Dec; 16(12):1674-1685. PubMed ID: 32803862
[TBL] [Abstract][Full Text] [Related]
29. Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life.
Gates NJ; Rutjes AW; Di Nisio M; Karim S; Chong LY; March E; Martínez G; Vernooij RW
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012277. PubMed ID: 32104914
[TBL] [Abstract][Full Text] [Related]
30. The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER): Study Design and Protocol.
Xu X; Chew KA; Wong ZX; Phua AKS; Chong EJY; Teo CKL; Sathe N; Chooi YC; Chia WPF; Henry CJ; Chew E; Wang M; Maier AB; Kandiah N; Chen CL
J Prev Alzheimers Dis; 2022; 9(1):40-48. PubMed ID: 35098972
[TBL] [Abstract][Full Text] [Related]
31. Adherence to a lifestyle intervention - just a question of self-efficacy? Analysis of the AgeWell.de-intervention against cognitive decline.
Wittmann FG; Pabst A; Zülke A; Luppa M; Oey A; Boekholt M; Weise S; Fankhänel T; Kosilek RP; Brettschneider C; Döhring J; Lunden L; Wiese B; Hoffmann W; Frese T; Gensichen J; König HH; Kaduszkiewicz H; Thyrian JR; Riedel-Heller SG
Alzheimers Res Ther; 2024 Jun; 16(1):133. PubMed ID: 38909256
[TBL] [Abstract][Full Text] [Related]
32. Methodological challenges in designing dementia prevention trials - the European Dementia Prevention Initiative (EDPI).
Richard E; Andrieu S; Solomon A; Mangialasche F; Ahtiluoto S; Moll van Charante EP; Coley N; Fratiglioni L; Neely AS; Vellas B; van Gool WA; Kivipelto M
J Neurol Sci; 2012 Nov; 322(1-2):64-70. PubMed ID: 22818266
[TBL] [Abstract][Full Text] [Related]
33. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
Colditz GA
Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
[TBL] [Abstract][Full Text] [Related]
34. Multidomain lifestyle interventions for cognition and the risk of dementia: A systematic review and meta-analysis.
Meng X; Fang S; Zhang S; Li H; Ma D; Ye Y; Su J; Sun J
Int J Nurs Stud; 2022 Jun; 130():104236. PubMed ID: 35395572
[TBL] [Abstract][Full Text] [Related]
35. Future directions in Alzheimer's disease from risk factors to prevention.
Imtiaz B; Tolppanen AM; Kivipelto M; Soininen H
Biochem Pharmacol; 2014 Apr; 88(4):661-70. PubMed ID: 24418410
[TBL] [Abstract][Full Text] [Related]
36. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165
[TBL] [Abstract][Full Text] [Related]
37. Multidomain interventions for risk reduction and prevention of cognitive decline and dementia: current developments.
Röhr S; Kivipelto M; Mangialasche F; Ngandu T; Riedel-Heller SG
Curr Opin Psychiatry; 2022 Jul; 35(4):285-292. PubMed ID: 35703256
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
